Cancer Research

Tumor targeting compound clinical trial results presented at conference

Published in Cancer Weekly, December 21st, 2004

NeoPharm, Inc., (Nasdaq:NEOL) announced that new and updated phase I/II trial data for its tumor-targeting compound IL13-PE38QQR were presented by John H. Sampson, MD, PhD, associate professor of surgery and assistant professor of pathology at Duke University on at the 9th Annual Meeting of the Society for Neuro-Oncology.

The oral presentation was entitled "Convection-Enhanced Delivery of IL13-PE38QQR in Malignant Glioma: Comparison of Observed and Predicted Drug Distribution."

"We are pleased with the results of this phase I study," said Gregory P. Young, NeoPharm's president and chief executive officer. "Optimizing catheter positioning in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry